Text Only
Full media Version

The Emergency Contraception Website - Your website for the "Morning After"

EC in the News



  • European Medicines Agency recommends OTC availability for ellaOne.
  • European Medicines Agency reverses its decision on changing the LNG EC label to say that the product does not work in heavier women; NorLevo label will revert back to its original version. Read the EMA decision here.
  • US Supreme Court rules in favor of Hobby Lobby; family-owned corporations are not required to pay for insurance coverage under the Affordable Care Act.
  • The US Supreme Court hears arguments in the Hobby Lobby case, in which a private corporation seeks to avoid the requirement to cover all methods of contraception under the Affordable Care Act (with a specific emphasis on EC and IUDs). Read NPR's coverage here.
  • FDA announces that generic manufacturers of LNG EC may apply for full OTC status; the box will say that the product will be for women ages 17 and up, but proof of age will not be required to purchase the product. Read the FDA letter.


  • European regulatory authorities approve a label change for NorLevo 1.5, stating that LNG EC doesn't work for women over 176 pounds, and removing the language that LNG EC can prevent implantation of a fertilized egg. Read the new label and coverage of the change in Mother Jones.
  • FDA approves Plan B One-Step for unrestricted sale. Read the FDA news release.
  • Federal Judge Korman grants Obama Administration's plan to make Plan B One-Step available OTC. Read the memo here.
  • Obama administration drops its appeal to Korman ruling; Plan B One-Step to be made available without restrictions in the US. Read the DOJ letter here and the letter from HHS here.
  • 2nd Circuit Court of Appeals orders that FDA must comply with Judge Korman's ruling to make 2-pill formulation of LNG EC available without restriction; grants stay regarding 1-pill formulation. Read the ruling here.
  • FDA approves Teva's amended application making Plan B One-Step available on the shelf for women ages 15 and older. Read the FDA and Teva press releases.
  • U.S. federal judge rules that the FDA must made LNG EC over the counter for all ages. Read the ruling here.


  • The American Academy of Pediatrics issues a policy statement supporting use of EC among adolescents, including advance provision.
  • FDA approves Watson's generic version of Plan B One-Step, called Next Choice One Dose
  • New York Times publishes an article explaining that EC does not block implantation of a fertilized egg.
  • Bill to imprison women for using EC is blocked in Honduran Congress
  • NARAL Pro-Choice New York presents "Plan B One-Step: Past, Present and Future" video
  • Pharmacists may present a barrier to teen girls accessing EC, through misinformation or failure to stock the medication.
  • U.S. study finds that teen can safely use EC without a prescription; there's no reason to keep it behind the counter.
  • Honduras Supreme Court upholds absolute ban on emergency contraception.
  • Center for Reproductive Rights re-opens lawsuit against FDA to remove unnecessary age restrictions on EC.
  • EC experts address President's Council of Advisors on Science and Technology Policy on the Plan B decision. Watch the webcast or read the testimony.







  • HRA Pharma commences US phase III trial of second-generation emergency contraceptive.
  • This site wins the 2006 Health Improvement Institute's Aesculapius Award, their top honor for a website or public service announcement that provides health information to the public.
  • Barr Launches Plan B OTC/Rx Dual-Label Product; Awarded 3 Years New Product Exclusivity
  • Premiere Emergency Contraception Website Ramps Up to Fill Education Void as 'Morning After Pill' Goes Over-the-Counter.

  • Kaiser Daily Women's Health Policy Report provides comprehensive coverage of the FDA decision and a summary of media coverage.

  • On August 24th, 2006, Plan B was approved by the FDA for nonprescription sale to those 18 and older in the United States. 

  • "Conscientious objection" legislation, which would allow pharmacists to refuse to fill certain prescriptions, including those for emergency contraception, was introduced in about half of state legislatures this year; none were approved.

  • Barr resubmits nonprescription Plan B application to FDA, and President Bush says that he supports the OTC switch but with age restrictions.

  • Research shows that physicians in clinics with religious affiliations are less likely to prescribe EC than those in nonreligious-affiliated clinics.

  • Barr cannot require pharmacies to abide by age restrictions for nonprescription sales of Plan B, CEO says.

  • Barr Laboratories to resubmit application for nonprescription sales of Plan B; FDA expected to act quickly.
  • Kaiser summarizes more national editorials and opinion pieces on nonprescription sales of Plan B here.
  • Mother Jones offers an updated timeline of the FDA decisions on Plan B (and other events in its political life in the US).
  • FDA scientist was told nonprescription Plan B application would be rejected 'to appease the administration's constituents,' deposition says.
  • Barr Laboratories, FDA to meet on Tuesday, August 8th in Washington, D.C. to discuss application for nonprescription sales of Plan B.  Kaiser provides a summary of national editorials and opinion pieces responding to the news that the FDA is reconsidering nonprescription sales of Plan B.
  • FDA chief calls for meeting with Barr subsidiary, says age restriction in nonprescription Plan B application should be raised to 18.  The sudden renewal of FDA interest in the Plan B application for over-the-counter status comes on the eve of von Eschenbach's confirmation hearings.  At the hearings, Senate Democrats question new FDA requirements for nonprescription Plan B application.
  • Felicia Stewart, a fierce advocate for expanded access to emergency contraception, died of cancer on April 13th.  This site contains accounts of her advocacy for women's health and fond memories from those who knew her.
  •  Wisconsin Attorney General seeks to join CRR as plaintiff in the lawsuit against the FDA over Plan B delay.
  •  Wal-Mart to stock EC Plan B at all pharmacies nationwide; Conn. health plans will not cover pharmacies not carrying EC, AG says.
  • New videos promote awareness of emergency contraception as tool to prevent unintended pregnancies among teens.  The videos can be downloaded from the CFHC website, www.cfhc.org.
  • Lawsuit to force US government to allow nonprescription sales of Plan B can continue.







  • The dedicated emergency contraception product NorLevo is now available over the counter in Norway. This is the first time that an EC product is available to women without contact with a clinician or pharmacist.
  • NARAL's new "Ten Minute Activist" website features immediate steps that activists can take online to learn more about reproductive rights issues and to advocate for choice. NARAL has also created a searchable database of all reproductive rights related bills introduced in state legislature.
  • Levonorgestrel (0.75 mg, pack of two) has now officially been added to The WHO Model List of Essential Drugs, 11th edition, 1999. (See Section 18: Hormones, other Endocrine Drugs, and Contraceptives.)
  • The Emergency Contraception Hotline Quality Assurance Study finds barriers to EC.
  • New Emergency Contraception Hotline materials available at no charge.
  • RHTP survey finds pharmacists and public favor widespread access to EC, oppose restrictive "conscience clause" legislation.




  • The New England Journal of Medicine of October 9, 1997, publishes a review article, "Emergency Postcoital Contraception" as well as an editorial, "Emergency Contraception - Expanding Opportunities for Primary Prevention".
  • Reproductive Health Technologies Project announces a year-long media campaign to educate women about Emergency Contraception.
  • FDA publishes notice in Federal Register declaring ECPs to be safe and effective.


  • A 24-hour toll-free emergency contraception hotline is launched on February 14, 1996.

This website is operated by the Office of Population Research at Princeton University and has no connection with any pharmaceutical company or for-profit organization.

website design by DDA